HUTCHMED Presents Exciting Data on Sovleplenib Phase III Study and Hematological Malignancy Programs at EHA2024 Congress
HONG KONG, SHANGHAI, and FLORHAM PARK, N.J. May 17, 2024 - HUTCHMED (China) Limited (HUTCHMED) (Nasdaq/AIM:HCM; HKEX:13) has announced its latest groundbreaking advancements in cancer research. The company will present the highly anticipated topline and subgroup results from the ESLIM-01 Phase III study of sovleplenib, along with new and updated data related to novel investigational hematological malignancy therapies HMPL-306, HMPL-760, and tazemetostat, at the upcoming European Hematology Association (EHA) Hybrid Congress. This prestigious event will take place on June 13-16, 2024, in Madrid, Spain, and online.
In addition to the ESLIM-01 study, HUTCHMED has made significant strides with its other research programs. The company has submitted a New Drug Application (NDA) for savolitinib in China, specifically for the treatment of locally advanced or metastatic MET Exon 14 NSCLC in both treatment-naive and previously treated patients. This oral presentation at the European Lung Cancer Congress 2024 highlighted Phase IIIb data demonstrating a median progression-free survival (PFS) of 13.7 months and a median overall survival (OS) that has not yet been reached in treatment-naive patients.
Furthermore, HUTCHMED has initiated the registration stage of the ESLIM-02 Phase II/III clinical trial of sovleplenib in adult patients with warm antibody autoimmune hemolytic anemia (wAIHA) in China. This trial aims to explore the efficacy and safety of sovleplenib as a potential treatment option for wAIHA, a rare and severe blood disorder.
The upcoming EHA2024 Congress provides a platform for HUTCHMED to showcase its cutting-edge research and commitment to improving patient outcomes in hematological malignancies. The company’s world-class scientists and researchers will present the results of the ESLIM-01 Phase III study, which investigated the efficacy and safety of sovleplenib, an innovative treatment option for patients with advanced hemangioendothelioma. The topline and subgroup data from this study are highly awaited and have the potential to revolutionize the field of cancer therapeutics.
Additionally, HUTCHMED will share promising updates on its investigational hematological malignancy therapies. HMPL-306, a highly potent and selective inhibitor of FGFR1-3, has shown encouraging results in preclinical models of hematological malignancies. HMPL-760, an oral small-molecule inhibitor, targets both the wild-type and mutant forms of FLT3 and CDK, and has exhibited promising anti-tumor activities in preclinical studies. Tazemetostat, an EZH2 inhibitor, is currently being evaluated in multiple clinical trials for patients with hematological malignancies such as follicular lymphoma and diffuse large B-cell lymphoma.
The combination of these exciting research programs highlights HUTCHMED’s dedication to finding innovative treatments for cancer patients. HUTCHMED’s scientific prowess and commitment to improving patient outcomes make it a leading force in the field of oncology research.
In conclusion, the upcoming presentation at the EHA2024 Congress on the ESLIM-01 Phase III study, as well as the latest data on HMPL-306, HMPL-760, and tazemetostat, showcases HUTCHMED as a frontrunner in cancer research. The company’s commitment to finding novel therapeutic options for patients with hematological malignancies offers hope and potential breakthroughs in the fight against cancer.
Comments